STARSOURCE MULTITRADE LIMITED — Interim / Quarterly Report 2021

Jan 28, 2021

==> picture [452 x 90] intentionally omitted <==

Date: 28[th] January, 2021

To, Bombay Stock Exchange Limited Department of Corporate Services 25[th] Floor, P. J. Towers, Dalal Street, Mumbai-400001

Script Id : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter ended 31[st] December, 2020 as under -

1.	Regulation 33	Un-audited Quarterly for the Quarter ended 31/12/2020 along with Limited Review Report issued by our Statutory Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 28/01/2021

You are requested to take this on your records.

Thanking you.

Yours Faithfully,

==> picture [235 x 118] intentionally omitted <==

Encl: as above

==> picture [546 x 109] intentionally omitted <==

LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of M/S CHEMO PHARMA LABORATORIES LTD. , Mumbai for the quarter ended 31[st ] December, 2020. This Statement is the responsibility of the Company’s management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

==> picture [526 x 158] intentionally omitted <==

==> picture [479 x 55] intentionally omitted <==

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DECEMBER 2020

			(Rupees in Thousand)	(Rupees in Thousand)	(Rupees in Thousand)	(Rupees in Thousand)	(Rupees in Thousand)	(Rupees in Thousand)
Sr. No.	Particulars		Quarter Ended			Nine Months Ended		Year Ended
			31st Dec., 2020	30th Sept 2020	31st Dec., 2019	31st Dec., 2020	31st Dec., 2019	31st March 2020
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I II III	Revenue from Operations							-
	Other Income		1,116	1,428	1,499	4,106	7,109	9,967
	Total Revenue(I + II)		1,116	1,428	1,499	4,106	7,109	9,967
IV	Expenses
	(1)	Cost Materials consumed	-	-	-	-	-	-
	(2)	Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3)	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4)	Employee Benefits Expenses	434	216	574	896	1,409	1,813
	(5)	Depreciation and Amortisation Expenses	-	-	-	-	-	231
	(6)	Administrative and Other Expenses	233	200	242	907	1,740	2,982
	(7)	Finance Costs	-	-	-	-	-	-
	Total Expenses		667	416	816	1,803	3,149	5,026
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax(III - IV)		449	1,012	683	2,303	3,960	4,941
VI	Exceptional Items		-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)		449	1,012	683	2,303	3,960	4,941
VIII	Extra OrdinaryItems		-	-	-	-	-	-
IX	Profit/(Loss) before Tax(VII-VIII)		449	1,012	683	2,303	3,960	4,941
X	Tax Expenses
	(1)Current Tax		-	-	-	-	-	760
	(2)Tax Adjustment Previous Year		-	-	-	-	-	30
	(3)Deffered Tax		-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)		449	1,012	683	2,303	3,960	4,151
XII	Profit/(Loss)from discontinuingoperations		-	-	-	-	-	-
XIII	Tax Expenses of discontinuingoperations		-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)		-	-	-	-	-	-
XV	Profit/(Loss) for theperiod(XI - XIV)		449	1,012	683	2,303	3,960	4,151
XVI	Other Comprehensive Income A (i) Itmes that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be reclassified to profit or loss B (i) Items that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be reclassified to profit or loss		-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period		449	1,012	683	2,303	3,960	4,151
XVIII	Earnings per Share : (1) Basic (2) Diluted		0.30	0.67	0.46	1.54	2.64	2.77

Notes :

• 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.

• 2 The above Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2020 have been reviewed report by the Audit Committee in their Meeting held on 28.01.2021 and approved by the Board of Directors of its Meeting held on 28.01.2021. The Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.

• 3 The Company is not having any Subsidary Company.

• 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo Pharma Laboratories Limited Place : Mumbai Date : 28th January, 2021

==> picture [469 x 48] intentionally omitted <==

RECONCILIATON OF STANDALONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2020

	(Rs. In Thousand)	(Rs. In Thousand)	(Rs. In Thousand)	(Rs. In Thousand)	(Rs. In Thousand)	(Rs. In Thousand)
PARTICULARS	STANDALONE
	UNAUDITED QUARTER ENDED			NINE MONTHS ENDED		AUDITED
						YEAR ENDED
	**31.12.2020 **	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
Reconciliation of Profit After Tax as reported earlier:
Net Profit/ (Loss) for the Period(asper AS)	449.00	1,012.00	683.00	2,303.00	3,960.00	4,151
Benefit /(Charge):	-	-	-	-	-	-
Impact of Deferred Income(Government Grant)Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-
Impact of Actuarial Gain/Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit/ (Loss) for the Period(asper AS)	449.00	1,012.00	683.00	2,303.00	3,960.00	4,151

==> picture [239 x 65] intentionally omitted <==

Mumbai, 28th January, 2021